BeiGene, Ltd. , an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Beigene stock last closed at $230.98, up 1.24% from the previous day, and has increased 75.17% in one year. It has overperformed other stocks in the Biotechnology industry by 1.54 percentage points. Beigene stock is currently +77.73% from its 52-week low of $129.96, and -19.77% from its 52-week high of $287.88.
At the moment, there are 1.39B shares of ONC outstanding. The market capitalization of ONC is $24.67B. In the past 24 hours, 519,865 ONC shares were traded.
How to Buy Beigene Stock
Wondering how to invest in Beigene stock? Here's how.
Choose where to buy Beigene stock: You need to choose an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you figure out where to buy Beigene stock.
Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Put funds into your investment account: Pick your payment method and add your information.
Evaluate Beigene stock: The Beigene ticker symbol is ONC. Is Beigene stock a good investment? Should you buy shares of ONC? How do ONC's underlying business fundamentals look? Do top analysts think Beigene is a good buy? Why has ONC's stock price moved recently? (Hint: Our stock analysis website can help you understand if ONC is a good stock to buy).
Place your ONC purchase: Decide if you will purchase ONC shares at the current market price or use a limit order to buy ONC stock at a specific price.
Monitor your ONC position: Create a watchlist to get the latest news on your new investment in Beigene shares.
Step 1: Choose where to buy Beigene stock
You will need an online brokerage account in order to access the NASDAQ market and buy ONC shares.
A brokerage account enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to world financial markets: From Tech to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you are able to invest in ONC stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Beigene stock
After you have figured out the best place to buy Beigene stock, it's very important to evaluate their stock prior to buying, so you truly wrap your head around the risk as well as the upside.
Beigene quick stats
ONC Price
$230.98
1w %
10.88%
1y %
75.17%
5y %
46.72%
P/E
-491.45x
P/B
7.4x
P/S
6.38x
PEG
N/A
Revenue
$3.81B
Earnings
-$644.79M
Fore. Rev. Growth
23.96%
Fore. Earn. Growth
N/A
Market Cap
$24.67B
Next Earnings
N/A
Next Dividend
N/A
Fundamentals of ONC
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on ONC's stock page.
Is ONC stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge ONC's true value.
Using relative valuations methods:
ONC could be overvalued based on its P/B ratio of 7.4x, relative to Biotechnology industry P/B ratio of 4.05x
There are more short-term assets than short-term liabilities on the ONC balance sheet.
ONC has $2.63B in cash and short term investments. This is enough to cover its annual cash burn of $633.29M.
There are more short-term assets than long-term liabilities on the ONC balance sheet.
ONC profit margin has gone up from -35.9% to -16.9% in the past year.
ONC has cash burn of 633294000. It has enough cash and short-term investments to cover this for at least one year.
Negative Health Checks:
ONC has a relatively high debt to equity ratio of 0.78.
Total ONC debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy ONC stock
Out of 7 Equities analysts who track ONC, the consensus analyst rating on Beigene is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Latest ONC Analyst Forecasts
Yaron Werber, a bottom 10% analyst from TD Cowen maintains ONC with a strong buy rating and raises their ONC price target from $254.00 to $260.00, on Nov 13, 2024.
Jessica Fye, a top 5% analyst from JP Morgan maintains ONC with a strong buy rating and raises their ONC price target from $200.00 to $235.00, on Oct 22, 2024.
JP Morgan's Jessica Fye raised their price target on Beigene (NASDAQ: BGNE) by 17.5% from $200 to $235 on 2024/10/22. The analyst maintained their Strong Buy rating on the stock.
Following indications from Iqvia prescription data suggesting ongoing growth for Beigene's primary product in the U.S., Fye raised their Q3 Brukinsa sales forecast to $672M.
In addition to the company's authorized products offering "significant valuation support," the analyst anticipates a number of near-term catalysts that could increase investor interest.
Footnotes
Brukinsa is a targeted therapy used to treat certain types of blood cancers, specifically B-cell lymphomas and leukemias.
You can dive deeper into what analysts are forecasting on the Beigene stock forecast page.
ONC Technicals
SMA10
225.42
SMA20
243.65
SMA50
246.48
SMA100
222.14
SMA200
207.69
MACD
-6.2
MACD Signal
-4.59
MACD Histogram
-1.61
RSI
45.19
Stochastic %K
41.28
Stochastic %D
44.54
StochRSI %K
46.88
StochRSI %D
49.95
Is ONC Making Money?
Last year, ONC revenue was $3.81B. Over the last five year, ONC's revenue has increased by 54.83% per year. This was faster than the Biotechnology industry average of 44.43%.
No, Beigene doesn't provide an income stream by paying out dividends.
What do other traders have to say about ONC?
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your ONC purchase
You have two primary types of orders:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are generally fine for most investors.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a given price limit, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you need more info about buying stocks on eToro, watch the helpful video below:
As of Apr 17, 2025, it costs $230.98 to buy one share of Beigene stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.433 shares of ONC.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.